Various studies have suggested the possible cardiovascular (CV) protective effects of the
pneumococcal vaccine (PV). Therefore, we conducted a meta-analysis to assess the …

Aims Streptococcus pneumoniae is the most common cause of community-acquired
pneumonia (CAP) and CAP-related mortality in adults. Pneumococcal vaccination (PV) …

Aims There are several guidelines that recommend pneumococcal vaccination (PPSV23
and/or PCV13) in adults with a history of cardiovascular disease (established heart failure …

Background Epidemiological studies suggest that there is a link between pneumococcal
infection and adverse cardiovascular outcomes such as myocardial infarction. Multiple …

Animal models and clinical studies suggest a mechanistic link between the pneumococcal
polysaccharide vaccine (PPV) and a cardiovascular protective effect. However, conflicting …

Background Cardiovascular benefits using the 23-valent pneumococcal polysaccharide
vaccine (PPV23) are controversial. This study assessed clinical effectiveness of PPV23 in …

Background It is vigorously debated whether pneumococcal polysaccharide vaccination
(PPV) reduces risk of acute coronary syndrome (ACS) events in patients with community …

Background: Diseases caused by Streptococcus pneumoniae (S. pneumoniae) continue to
cause substantial morbidity and mortality throughout the world. Whilst pneumococcal …

Background Research has shown that vaccination with Streptococcus pneumoniae reduced
the extent of atherosclerosis in experimental animal models. It is thought that …

Background: Based on promising results from laboratory studies, we hypothesized that
pneumococcal vaccination would protect patients from myocardial infarction. Methods: We …